Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
June 22, 2023
SECAUCUS, N.J., June 21, 2023 /PRNewswire/ — Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information
Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
April 28, 2023
SOURCE Quest Diagnostics Goal to improve patient outcomes through early, accurate detection of residual or
Precision Medicine World Conference 2023 Silicon Valley
January 12, 2023
Haystack’s co-founder and Chief Innovation Officer, Josh Cohen, will be participating in a panel discussion
Haystack Oncology Appoints Joel Kaufman as Chief Financial Officer
December 1, 2022
BALTIMORE, MD, December 1, 2022 – Haystack Oncology (“Haystack”), an oncology company that applies the next
Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
November 16, 2022
Liquid biopsy approach delivers unparalleled sensitivity and specificity for detection of low-frequency mutant molecules to
Applying precision technology to improve the detection of residual disease in cancer patients
September 22, 2022
Though early cancer diagnosis provides better outcomes for patients, many experience later disease recurrence following
